NEWARK, CA / ACCESS Newswire / March 28, 2026 / Protagonist Therapeutics, Inc. (Nasdaq:PTGX) ("Protagonist" or "the Company") today announced new one-year Phase 3 results for ICOTYDE ™ (icotrokinra) ...
One-year Phase 3 data for ICOTYDE to be presented at AAD 2026 demonstrate lasting skin clearance and a favorable safety profile in a once daily pill for moderate-to-severe plaque psoriasisResults furt ...
With groundbreaking design choices and writing, these are the JRPGs That Shaped Modern Gaming More Than Players Realized.
THE DEPARTMENT of Agriculture-Mindanao Inclusive Agriculture Development Project (DA-MIADP), with the backing of the World ...
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care ...
Johnson & Johnson presents new data showing high rates of complete skin clearance achieved at Week 24 and Week 52 in ICONIC-ADVANCE 1 and 2 ...
Frequent travel lifestyle impacts health, productivity, and balance. Learn how professionals manage stress, sleep, and ...
UCB, a global biopharmaceutical company, today announced new data in moderate-to-severe plaque psoriasis (PSO) at the 2026 American Academy of Dermatology (AAD) Annual Meeting in Denver, March 27–31.
The 8th Pay Commission is now functioning in New Delhi. It will submit recommendations on pay, allowances, and pensions ...
Here’s the latest on the Pearson gold heist mastermind’s guilty plea in court and Prime Minister Mark Carney and Ontario ...
3d
How The Pearson (LSE:PSON) Narrative Is Shifting As Analysts Rework Targets And Growth Assumptions
Analysts have been adjusting price targets on Pearson, with moves such as a cut to $13.90 and a new 1,300 GBp target helping ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results